Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (2)
  • Proteasome
    (2)
  • Amino Acids and Derivatives
    (1)
  • Histone Methyltransferase
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

a 924

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    7
    TargetMol | Inhibitors_Agonists
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
A 924
A-924, A924
T2645965132-74-3
A 924 is an amino acid derivative with antineoplastic activity.
  • $1,520
6-8 weeks
Size
QTY
PR-924
T165681416709-79-9
PR-924 is a selective inhibitor of tripeptide epoxyketone immunoproteasome subunit LMP-7 (IC50: 22 nM). PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities. PR-924 covalently modifies proteasomal N-terminal threonine active sites.
  • $722
7-10 days
Size
QTY
CI 924
EINECS 279-174-7, CI-924, CI924
T3091779520-77-7
CI 924 is a lipid-lowering drug. CI 924 increased anti-atherosclerotic HDL and decreased VLDL at 600 mg/day.
  • $1,520
6-8 weeks
Size
QTY
Zetomipzomib
T374191629677-75-3
KZR-616, a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. KZR-616 has the potential for the research of multiple autoimmune diseases[1][2]. KZR-616 also inhibits MECL-1 subunit (IC50=623 nM) and constitutive proteasome β5 subunit (IC50=688 nM). KZR-616 maintains LMP7 and LMP2 selective inhibition in MOLT-4 cells. KZR-616 (250 nM) shows a comparable cytokine inhibition profile peripheral blood mononuclear cells (PBMC)[1].KZR-616 is an immunoproteasome-selective inhibitor identified based on the optimization of ONX-0914 and PR-924 [3]. KZR-616 (5 mg/kg; i.v.; dosing was repeated on days 6, 8, 11, and 13) shows efficacy in the anticollagen antibody induced arthritis (CAIA) model[1]. [1]. Johnson HWB, et al. Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide). J Med Chem. 2018 Dec 27;61(24):11127-11143. [2]. Muchamuel T, et al. FRI0296 Kzr-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE). Annals of the Rheumatic Diseases 2018;77:685. [3]. Xi J, et al. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019;182:111646.
  • $8,450
10-14 weeks
Size
QTY
Ethyl 3-(dimethylamino)acrylate
T66876924-99-2
Ethyl 3-(dimethylamino)acrylate is a useful organic compound for research related to life sciences. The catalog number is T66876 and the CAS number is 924-99-2.
    Inquiry
    ZZM-1220
    T79776
    ZZM-1220, a covalent inhibitor of histone lysine methyltransferase G9a/GLP, exhibits IC50 values of 458 nM for G9a and 924 nM for GLP. It effectively inhibits H3K9me2 in cells, induces apoptosis in triple-negative breast cancer (TNBC) cells, and arrests the cell cycle at the G2/M phase [1].
    • Inquiry Price
    Inquiry
    Size
    QTY
    N-Nitroso-Di-n-Butylamine-d18
    TMIJ-03501219798-82-9
    N-Nitroso-Di-n-Butylamine-d18 is a deuterated compound of N-Nitroso-Di-n-Butylamine. N-Nitroso-Di-n-Butylamine has a CAS number of 924-16-3.
    • Inquiry Price
    20 days
    Size
    QTY